AI VIVO (Cambridge, UK) says it is looking for pharma and biotech companies interested in working on therapeutic candidates that its artificial intelligence has identified as “top-ranked” for COVID-19.
The company says it has found that multiple groups around the world already are conducting clinical trials for 41 of the candidate drugs from its top-ranked list for COVID-19. AI VIVO officials say the overlap is significant because its ranking system is based on the company’s phenotypic drug discovery methodology and does not rely on any prior knowledge or known information related to the disease or compounds.
“This is a great validation of AI VIVO’s phenotypic approach to modeling diseases and the effects of drugs,” AI VIVO CEO Peyman Gifani said in a news release.
“Our panel of experts believes there are combinations of other top-ranked drugs that will be more effective than any single drug and we are keen to share our results with pharma companies and clinical trial investigators to support the fight against COVID-19. We are also offering to cross-check the candidates from other investigators to help predict combinations to improve drug efficacy, reduce undesirable side effects and optimize the dosage.’’
AI VIVO is now seeking companies to test candidates identified by the platform as top-ranked to provide anti-viral, anti-inflammatory and cytokine storm suppressive effects against COVID-19. The company has also compiled a list of drug combinations from its top-ranked list and is looking to share the results with pharma companies and clinical trial investigators.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development